Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07444892 · ClinicalTrials.gov registry record · Phase 2
Levodopa for Diabetic Retinopathy
A Phase 2 study of Diabetic Retinopathy, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 1
- Study location
NCT07444892: Completed Phase 2 study of Diabetic Retinopathy, sponsored by Emory University.
NCT07444892 is a Phase 2 study of Diabetic Retinopathy that has completed, run by Emory University. The registered enrollment target is 230 participants, below the 1,672-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07444892, a Phase 2 study of Diabetic Retinopathy, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine optimum dosing strategies of levodopa and determine the physiologic mechanisms that provide the therapeutic response to restore abnormalities in the electrical conductivity of the retina in people with diabetes and no clinically visible retinopathy.
Primary Outcome
Full-field electroretinography (ERG) will be performed to assess rod-mediated retinal function. A skin electrode placed below the eye records the response to flash stimuli. Participants will be dark-adapted for 10 minutes to sensitive retinal rod pathways. Flash stimuli will consist of dim (1.13 Td) or bright (85 Td) flashes to reveal early dysfunction in DR.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Levodopa
Study Locations (1)
Georgia
- Atlanta VA Medical Center - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2022-04-18 |
| Est. Completion | 2025-11-17 |
| Phase | Phase 2 |
What the finished NCT07444892 record still lists
NCT07444892 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 1,672-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07444892 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT07444892 about?
NCT07444892 is a clinical study titled "Levodopa for Diabetic Retinopathy". The purpose of this study is to determine optimum dosing strategies of levodopa and determine the physiologic mechanisms that provide the therapeutic response to restore abnormalities in the electrical conductivity of the retina in people with diabetes and no clinically visible retinopathy.
What is the current status of trial NCT07444892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2022-04-18. Estimated completion is 2025-11-17.
What conditions does trial NCT07444892 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT07444892?
The interventions under investigation include: Placebo (DRUG), Levodopa (DRUG).
Who is sponsoring clinical trial NCT07444892?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07444892 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07444892's enrollment target sits among peer trials
230 27th of 57 higher than 31 of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
RECRUITING · Phase 2
-
Sleep, Diabetic Retinopathy and Melatonin
RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
A Study of PER-001 in Participants With Diabetic Retinopathy
ACTIVE NOT RECRUITING · Phase 2
-
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI